Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067161 | 0.87 | KCNA5 (0.39) | FFAR1KCNA5ALDH1A1GAAL3MBTL1 | |
| SCHEMBL3069083 | 0.87 | KCNA5 (0.44) | FFAR1KCNA5ALDH1A1GAAPRKCA | |
| SCHEMBL3069248 | 0.86 | CNR2 (0.37) | FFAR1ALDH1A1 | |
| SCHEMBL3071336 | 0.86 | FFAR1 (0.37) | FFAR1KCNA5ALDH1A1GAAPRKCA | |
| SCHEMBL3066645 | 0.85 | KCNA5 (0.43) | FFAR1KCNA5PRKCAPRKCDVNN1 | |
| SCHEMBL3076912 | 0.85 | FFAR1 (0.43) | FFAR1KCNA5ALDH1A1L3MBTL1PRKCA | |
| SCHEMBL3078927 | 0.85 | FFAR1 (0.38) | FFAR1KCNA5ALDH1A1PRKCAPRKCD | |
| SCHEMBL3067158 | 0.85 | FFAR1 (0.36) | FFAR1KCNA5L3MBTL1PRKCAPRKCD | |
| SCHEMBL3074998 | 0.85 | MEN1 (0.40) | FFAR1KCNA5ALDH1A1L3MBTL1PRKCA | |
| SCHEMBL3076028 | 0.85 | FFAR1 (0.37) | FFAR1KCNA5ALDH1A1GAAPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267555-A1 | Fungicidal mixtures II | BASF SE (DE) | 2010-10-21 | — | — | US | claimed |
| EP-2222169-A2 | FUNGICIDAL MIXTURES II | BASF SE (DE) | 2010-09-01 | — | — | EP | claimed |
| WO-2009063075-A2 | FUNGICIDAL MIXTURES II | BASF SE (DE) | 2009-05-22 | — | — | WO | claimed |
| WO-2005123727-A1 | 3-ARYL-3-HYDROXY- AND 3-ARYL-3-OXOPROPIONIC ACID ESTERS AS FUNGICIDES | CROPSOLUTION, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050277663-A1 | 3-Aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides | ATP CAPITAL LP | 2005-12-15 | — | — | US | claimed |
| US-20100267555-A1 | Fungicidal mixtures II | BASF SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2222169-A2 | FUNGICIDAL MIXTURES II | BASF SE (DE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009063075-A2 | FUNGICIDAL MIXTURES II | BASF SE (DE) | 2009-05-22 | — | — | WO | disclosed |
| US-20050277663-A1 | 3-Aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides | ATP CAPITAL LP | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277663-A1 | 3-Aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides | CYP21A2, HAO1, AHR | FFAR1 222/4885KCNA5 432/4885ALDH1A1 99/4885 |
| US-20100267555-A1 | Fungicidal mixtures II | CBR3, CBR1, NOX3 | FFAR1 556/4885KCNA5 605/4885ALDH1A1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.